Loading
A phase 1/2 trial in triple-negative breast cancer, run by Texas Tech University Health Sciences Center, not yet recruiting.
Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers is a phase 1/2, randomised interventional study registered as NCT05806385 by Texas Tech University Health Sciences Center, with a registry enrolment figure of 36 participants, started 2026-03 and due to reach its primary completion in 2027-01. Interventions recorded: Cryoablation; Cryoablation combined with PD1 Inhibitor. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Diagnoses: Invasive carcinoma, ER -, PR-, HER2- (triple negative)". No results are recorded here; the registry entry is the source.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.